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background: Recombinant Activated Factor VII (rFVIIa) is a Food and Drug administration (FDA) approved drug for treatment of refractory 
bleeding in Hemophilia. Occasionally this has also been used for hemostasis during cardiac surgery. There is growing concern for increased risk 
of thromboembolic complications with its use during Left ventricular Assist Device (LVAD) placement. We reviewed our experience with rFVIIa 
administration during implantation of LVAD and evaluated its effectiveness in hemostasis and the risk of thromboembolic events. 
Methods: A retrospective study was conducted reviewing records of 65 patients who received either a HeartMate-II (HM-II) or HeartWare (HW) 
LVAD between 2008 and August 2011. Patients were divided into 2 groups based on rFVIIa administration during surgery. All data on patient 
demographics, transfusion requirements, laboratory values before and after rFVIIa administration were recorded. Significant thromboembolic events 
including Pulmonary Embolism, Stroke and Deep venous thrombosis were documented. The incidence of thromboembolic events was compared in 
the two groups. 
results: -The mean age of study population was 54.7 years with 52 male and 13 female patients. 57 patients received HM-II and 8 patients 
received HW. 20 patients (30.7%) received rFVIIa with a dose range between 27mcg/kg to 145mcg/kg. There was statistically significant decrease in 
Prothrombin time (from mean of 15.2 to 10.5 seconds, p-value of 0.0003) and activated partial thromboplastin time (from mean of 34.5 seconds 
to 31.1, p-Value of 0.09) with the administration of rFVIIa. The incidence of thromboembolic events was significantly higher in the rFVIIa group (30%) 
as compared to the other group (15.9%). In rFVIIa group, 4 patients had stroke and 2 patients had DVT. The 30 day morality in the rFVIIa group was 
15% (n 3) as compared to no mortality seen in the other group. 
conclusions: Our study concludes that rFVIIa is very effective in controlling intra-operative bleeding however there is a significantly increased risk 
of thromboembolic complications associated with its use. We suggest very cautious and judicious use of rFVIIa during LVAD placement. 
